Mycenax Biotech - Asset Resilience Ratio

Latest as of September 2025: 0.04%

Mycenax Biotech (4726) has an Asset Resilience Ratio of 0.04% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Mycenax Biotech (4726) strategic asset index to assess the company's strategic physical and investment asset allocation.

Liquid Assets

NT$1.20 Million

≈ $37.81K USD Cash + Short-term Investments

Total Assets

NT$3.33 Billion

≈ $104.88 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2017–2024)

This chart shows how Mycenax Biotech's Asset Resilience Ratio has changed over time. See Mycenax Biotech net asset quality index to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Mycenax Biotech's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 4726 company net worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	NT$0.00	0%
Short-term Investments	NT$1.20 Million	0.04%
Total Liquid Assets	NT$1.20 Million	0.04%

Asset Resilience Insights

Limited Liquidity: Mycenax Biotech maintains only 0.04% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Mycenax Biotech Industry Peers by Asset Resilience Ratio

Compare Mycenax Biotech's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Cyclacel Pharmaceuticals Inc NASDAQ:CYCC	Biotechnology	-55.36%
Krystal Biotech Inc NASDAQ:KRYS	Biotechnology	23.06%
Verona Pharma PLC ADR NASDAQ:VRNA	Biotechnology	0.00%
Centessa Pharmaceuticals PLC ADR NASDAQ:CNTA	Biotechnology	33.37%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
Hebei Changshan Biochem Pharma SHE:300255	Biotechnology	-0.03%
BB Biotech AG SW:BION	Biotechnology	0.05%

Annual Asset Resilience Ratio for Mycenax Biotech (2017–2024)

The table below shows the annual Asset Resilience Ratio data for Mycenax Biotech.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	0.25%	NT$8.50 Million ≈ $267.80K	NT$3.37 Billion ≈ $106.12 Million	-3.72pp
2023-12-31	3.97%	NT$149.62 Million ≈ $4.71 Million	NT$3.77 Billion ≈ $118.79 Million	+3.58pp
2022-12-31	0.39%	NT$17.32 Million ≈ $545.55K	NT$4.45 Billion ≈ $140.29 Million	+0.12pp
2021-12-31	0.27%	NT$8.50 Million ≈ $267.80K	NT$3.14 Billion ≈ $98.90 Million	+0.20pp
2020-12-31	0.07%	NT$1.20 Million ≈ $37.81K	NT$1.75 Billion ≈ $55.22 Million	-5.95pp
2019-12-31	6.02%	NT$84.76 Million ≈ $2.67 Million	NT$1.41 Billion ≈ $44.36 Million	-2.79pp
2018-12-31	8.81%	NT$98.60 Million ≈ $3.11 Million	NT$1.12 Billion ≈ $35.25 Million	-13.48pp
2017-12-31	22.30%	NT$292.69 Million ≈ $9.22 Million	NT$1.31 Billion ≈ $41.36 Million	--

pp = percentage points

About Mycenax Biotech

TWO:4726 Taiwan Biotechnology

Market Cap

$162.63 Million

NT$5.16 Billion TWD

Market Cap Rank

#17445 Global

#900 in Taiwan

Share Price

NT$24.90

Change (1 day)

+1.22%

52-Week Range

NT$24.60 - NT$40.05

All Time High

NT$68.00